AbbVie Inc. 8-K

What Happened

• AbbVie Inc. filed a Current Report on Form 8-K on April 3, 2026, announcing that its preliminary results for the quarter ended March 31, 2026 are expected to include $744 million of acquired in‑process R&D (IPR&D) and milestones expense on a pre-tax basis.
• That charge represents an unfavorable impact of $0.41 to both GAAP diluted earnings per share and adjusted non‑GAAP diluted earnings per share. AbbVie noted quarter results are not final and remain subject to closing procedures.

Key Details

• Acquired IPR&D and milestones expense (pre-tax): $744 million.
• EPS impact: negative $0.41 to GAAP diluted EPS and adjusted diluted EPS for Q1 2026.
• Adjusted diluted EPS guidance (full-year 2026) including the Q1 impact: $13.96 – $14.16.
• Adjusted diluted EPS guidance (Q1 2026) including the Q1 impact: $2.56 – $2.60. AbbVie does not routinely forecast acquired IPR&D and milestones expense due to timing uncertainty.

Why It Matters

• The one-time charge lowers reported and adjusted EPS for Q1 and reduces the mid-point of full‑year adjusted EPS guidance relative to prior exclusions of such charges. Investors should note these are preliminary figures and may change after quarter close.
• Because AbbVie excludes unpredictable acquired IPR&D and milestone expenses from its typical forecasting, future quarters could see similar volatility if additional deals or milestones occur. This impacts how investors interpret quarterly earnings and adjusted EPS comparisons.